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Alzheimer disease (AD) is a major threat of twenty-ﬁrst century that is responsible for the
majority of dementia in the elderly. Development of effective AD-preventing therapies are
the top priority tasks for neuroscience research. Amyloid hypothesis of AD is a dominant
idea in the ﬁeld, but so far all amyloid-targeting therapies have failed in clinical trials.
In addition to amyloid accumulation, there are consistent reports of abnormal calcium
signaling inAD neurons. AD neurons exhibit enhanced intracellular calcium (Ca2+) liberation
from the endoplasmic reticulum (ER) and reduced store-operated Ca2+ entry (SOC).These
changes occur primarily as a result of ER Ca2+ overload. We argue that normalization of
intracellular Ca2+ homeostasis could be a strategy for development of effective disease-
modifying therapies.The current review summarizes recent data about changes in ER Ca2+
signaling in AD. Ca2+ channels that are discussed in the current review include: inositol
trisphosphate receptors, ryanodine receptors, presenilins as ER Ca2+ leak channels, and
neuronal SOC channels. We discuss how function of these channels is altered in AD and
how important are resulting Ca2+ signaling changes for AD pathogenesis.
Keywords:Alzheimer disease, Ca2+ signaling, presenilins, endoplasmic reticulum, inositol trisphosphate receptors,
ryanodine receptors, store-operated Ca2+ channels, dantrolene
INTRODUCTION
Calcium (Ca2+) is one of the most important second messen-
gers in the nervous system. Ca2+-mediated signal transduction
connects membrane excitability and biological functions of neu-
rons ranging from proliferation, secretion, gene expression, ATP
production, cell death to memory formation and its loss. Act-
ing at the border of electrical and signaling “worlds” of the cell,
Ca2+-permeable channels play amajor role inmany key aspects of
neuronal functions. Due to the huge importance of the calcium as
the secondmessenger neurons utilizemany approaches to regulate
intracellular Ca2+ content, mainly via local signal transduction
pathways. Neuronal Ca2+ inﬂux can be maintained by different
Ca2+-permeable channels, such as voltage-gatedCa2+ channels of
plasma membrane, N-methyl-D-aspartate (NMDA) receptors, α-
amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA)
receptors, nicotinic receptors, store-operated Ca2+ channels
(SOC). Ca2+ can also be released from intracellular stores of endo-
plasmic reticulum (ER) via inositol-1,4,5-trisphosphate receptors
(InsP3R) and ryanodine receptors (RyanRs). Mitochondria also
play an important role in intracellular Ca2+ handling. Neurons
are highly susceptible to any changes in intracellular Ca2+ concen-
trations: insufﬁcient intracellular Ca2+ content lead to abnormal
functioning of neurons, whereas excessive Ca2+ levels cause cell
death (Berridge, 1998). Therefore, even small ﬂuctuations in
Ca2+ content can be very detrimental over long life of a neuron
(Khachaturian, 1989).
Alzheimer disease (AD) is the threat of twenty-ﬁrst century
that is responsible for the majority of senile dementia. AD pro-
gresses slowly and affects neurons in the brain. Currently there
are two main proteins whose dysfunctions and accumulation in
the brain are correlated with the disease progress. The ﬁrst is
40–42 long beta-amyloid (Aβ) peptides that constitute a major
part of neuritic plaques and cause excessive neurotoxicity. These
peptides are cleaved from the amyloid precursor protein (APP)
by β- and γ-secretases (Hardy and Selkoe, 2002). The second
protein is tau whose hyperphosphorylation results in misfolding
and forming of proteolysis-resistant neuroﬁbrillar tangles (NFTs).
Aβ40, Aβ42, and NFT are synaptotoxic to neurons and facilitate
cell death (Small and Duff, 2008). Although the exact mecha-
nism how Aβ40, Aβ42, and NFT mediate AD pathogenesis is not
fully understood, there are observations that link Aβ42 accumu-
lation with elevated Ca2+ levels in neuronal cytoplasm in vivo
(Kuchibhotla et al., 2008). It has been shown that oligomers of
Aβ is able to make Ca2+ permeable channels in plasma mem-
brane of neurons, therefore directly affecting intracellular Ca2+
concentration (Arispe et al., 1993). Recent publications state that
soluble oligomeric form of Aβ42 potentiate Ca2+ liberation from
the ER through the stimulated production of inositol trisphos-
phate (Demuro and Parker, 2013) and by stimulating synaptic
mGluR5 receptors (Renner et al., 2010).
There is another line of evidence coming from mouse mod-
els harboring presenilin’s mutations that AD-like symptoms and
synaptic dysfunction can occur due to Ca2+ accumulation in
the ER in the absence of Aβ pathology (Stutzmann et al., 2004;
Chakroborty et al., 2009; Zhang et al., 2010b). Early changes
in intraneuronal Ca2+ regulation are common observations in
AD patients (Emilsson et al., 2006; Stutzmann, 2007; Bezproz-
vanny andMattson, 2008). All these observations support calcium
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hypothesis of AD. This hypothesis was ﬁrst formulated in 1987
by Dr. Zaven Khachaturian who proposed that sustained changes
in intracellular calcium homeostasis provide the ﬁnal common
pathway for AD and age-associated brain changes (Khachaturian,
1987). Since that time many advances in our understanding of
Ca2+ signaling in AD have been obtained. New Ca2+ perme-
able channels have been identiﬁed, some of them directly linked
to AD. For example, it has been demonstrated that presenilins
encode passive ER Ca2+ leak channels (Tu et al., 2006) and a novel
Ca2+ channel called Ca2+ homeostasis modulator 1 (CALHM1)
has been linked to late-onset AD by genetic evidence (Dreses-
Werringloer et al., 2008). However, as it usually happens with new
ﬁndings, the existence of these novel Ca2+ channels and their role
inADhas been challenged. Themain purpose of the current paper
is to review recent publications in the ﬁeld of ER Ca2+ signaling
in the context of AD pathology. We will review the role of two
well accepted ER Ca2+ channels that release Ca2+ out of the neu-
ronal ER – InsP3R and RyanR. We will also discuss new ﬁndings
about the role of presenilins and neuronal SOC in neuronal func-
tion. Our focus will be on potential role of these channels in AD
pathology and as targets for development of disease-modifying
therapies.
INOSITOL TRISPHOSPHATE RECEPTORS
The ﬁrst observation of exaggerated InsP3R-mediated Ca2+
release from ER in ﬁbroblasts fromAD patients has been obtained
even before the identiﬁcation of presenilins (Ito et al., 1994). It
was later shown that these ﬁbroblasts (from patients AG06840
and AG06848) harbor A246Q mutation in PSEN1 (description
in Coriell Institute Cell Database). The studies with ﬁbroblasts
taken from PS1-M146V knockin mice and with Xenopus oocytes
expressing human presenilin proteins 1 and 2 (PS1 and PS2)
mutant constructs showed an upregulation of InsP3R-mediated
Ca2+ release (Leissring et al., 1999a,b, 2000). Experiments in corti-
cal neurons using whole-cell patch clamp and rapid Ca2+ imaging
in brain slices from mutant PS1-M146V mice also demonstrated
almost threefold exaggeration of ER Ca2+ liberation by photolysis
of caged InsP3 and accompanying enhancement of Ca2+-evoked
outward membrane currents (Stutzmann et al., 2004). Similar
results of enhanced InsP3-evoked Ca2+ signals were observed in
3xTg-ADmice (Stutzmann et al., 2006). Important to note that the
Ca2+ disturbances were already observed in the 3xTg-AD mice at
the age of 4–6 weeks that precedes appearance of Aβ plaques and
NFTs by several months (Oddo et al., 2003). Later on it has been
reported that in non-neuronal DT40 and Sf9 cell models familial
AD (FAD) associatedmutations PS1-M146L andPS2-N141I inter-
act with InsP3R and exert stimulatory effects on its gating activities
(Cheung et al.,2008). Inmore recent study the samegrouphaspro-
posed that stimulation of InsP3R gating by expression of mutant
PS1-M146L in DT40 and PC12 cells results in generation of reac-
tive oxygen species (ROS; Muller et al., 2011). Authors report that
exaggerated Ca2+ signaling through InsP3R-PS interaction and
generation of ROSmay contribute to the pathology of AD (Muller
et al., 2011).
Important to note the recent study showing that intracellu-
lar application of Aβ oligomers into Xenopus oocytes stimulates
G-protein-mediated InsP3 production and consequent Ca2+
release from the ER, that is cytotoxic (Demuro and Parker, 2013;
depicted in Figure 1). Also, it was reported thatAβ oligomers stim-
ulate synaptic mGluR5 receptors linked with InsP3 production
(Renner et al., 2010). Although detrimental effect of Aβ oligomers
on neurons has been extensively studied and many publications
demonstrated that Aβ aggregates promote the increase in cytosolic
Ca2+ content of neurons (Walsh et al., 2002; Demuro et al., 2005,
2010; Deshpande et al., 2006; Simakova andArispe, 2007; Bezproz-
vanny and Mattson, 2008; Green and LaFerla, 2008; Kuchibhotla
et al., 2008), the exact mechanism how Aβ contributes to disrup-
tion of Ca2+ signaling is not known. Therefore, the studies of
Demuro and Parker (2013) and Renner et al. (2010) could poten-
tially provide a connection between amyloid and overactivation of
InsP3R-mediated Ca2+ signals.
RYANODINE RECEPTORS AND EFFECTS OF DANTROLENE
Ryanodine receptors are expressed in soma, proximal dendrites as
well as in distal processes and spines. RyanRs activity is enhanced
in dendrites and synaptic spines from presymptomatic 3xTg-AD
and TASTPM (APPsw; PS1.M146V; Howlett et al., 2004) AD mice
(Goussakov et al., 2010). RyanR-mediated Ca2+-induced Ca2+
release (CICR) in 3xTg-AD mice is exaggerated in response to
synaptic stimulation, including NMDAR-mediated Ca2+ inﬂux
(Goussakov et al., 2010). These authors proposed that enhanced
synaptic CICRmay alter synaptic function andmay be recognized
FIGURE 1 | Proposed role of ER Ca2+ signaling in the pathogenesis of
AD.The cartoon represents the Ca2+ hypothesis of AD that places
presenilins (PS) in the center of AD pathogenesis. Amyloid oligomers
stimulate InsP3R-mediated Ca2+ release from ER by activating synaptic
mGluR5 receptors and by stimulating G-protein-mediated InsP3 production.
Our laboratory has shown that presenilins function as ER Ca2+ leak
channels and FAD associated PS mutations disrupt this function, causing
overloading of ER with Ca2+. Similar ER Ca2+ overload occurs as a result
of neuronal aging process. The ﬁrst physiological response to ER Ca2+
elevation is compensatory increase in expression and/or activity of inositol
trisphosphate receptors (InsP3R) and ryanodine receptors (RyanRs). The
second response to ER Ca2+ overload is reduction in store-operated Ca2+
(SOC) entry, a mechanism involved in reﬁlling of ER Ca2+ stores (mediated
by Orai andTRP channels). We hypothesize that these initially
compensatory and protective mechanisms of ER Ca2+ signaling become
pathogenic in aging neurons and eventually lead to synaptic dysfunction,
synaptic loss and neurodegeneration.
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as an early pathogenic factor in AD (Goussakov et al., 2010).
Increased levels of RyanR are at least partially responsible for
enhancedCICR inADneurons. Increased expression of RyanRhas
been described in human AD cases and in patients with mild cog-
nitive impairment (MCI; Kelliher et al., 1999; Bruno et al., 2012).
Elevated RyanR2 expression, cognitive decline, and synaptic loss
observed in MCI patients are mirrored by an increase in RyanR2
expression and Ca2+ release in presymptomatic AD mice (Kelli-
her et al., 1999; Stutzmann et al., 2006; Chakroborty et al., 2009;
Zhang et al., 2010b). Recently, it has been suggested that increased
RyanR expression at early stages of ADmight play a role as a com-
pensatory mechanism to stabilize the preexisting synaptic deﬁcits
and normalize the depressed synaptic network (Chakroborty et al.,
2012b). Similar idea of elevated RyanR3 expression as a neuropro-
tective response to Aβ1–42 toxic effects has been suggested before
(Supnet et al., 2010).
Several studies addressed the role of RyanR in the context
of AD by using pharmacological agent dantrolene. Dantrolene
is an antagonist of the RyanR and is used clinically to treat
malignant hyperthermia, neuroleptic malignant syndrome, and
muscle spasms (Krause et al., 2004; Inan and Wei, 2010). In
the ﬁrst study the dantrolene was administered to 3xTg-AD
mice by intracerebroventricular (ICV) injection for 3 months
using an Alzet intracranial ventricular infusion system and then
subcutaneously three times per week for 8 month (Peng et al.,
2012). The authors state that dantrolene treatment signiﬁcantly
reduced both memory deﬁcits tested by Morris water maze test
and amyloid plaque load in the hippocampus in 13-month-old
3xTg-AD mice (Peng et al., 2012). The second work performed
sub-chronically short-term (4 weeks) treatment of AD models
(3xTg-AD and TASTPM) with dantrolene (Chakroborty et al.,
2012a). Using two-photon Ca2+ imaging and patch clamp record-
ings authors showed that dantrolene treatment normalized ER
Ca2+ signaling within somatic and dendritic compartment in
early and late-stage AD mice in hippocampal slice experiments
(Chakroborty et al., 2012a). The third study (Oules et al., 2012)
was performed with transgenic mice expressing human APP-
swe mutation (Tg2576). These authors observed that dantrolene
treatment diminished Aβ load, reduced histological lesions, and
slowed down learning andmemory deﬁcits in Tg2576mice (Oules
et al., 2012). These studies suggested that inhibition of RyanR
with dantrolene may exert beneﬁcial effects in the context of
AD pathology. However, opposite conclusion was obtained by
our laboratory in experiments with APPPS1 transgenic mouse
model (Thy1-APPKM670/671NL, Thy1-PS1L166P; Zhang et al.,
2010b). In these studies we discovered that long-term (start-
ing at 2 months of age) oral feeding of dantrolene exacerbated
plaque formation and resulted in loss of hippocampal synaptic
markers and neuronal deterioration in 8-month-oldAPPPS1mice
(Zhang et al., 2010b). How can these seemingly divergent obser-
vations that center on dantrolene be explained? It is difﬁcult to
directly compare these results due to different routes of dantro-
lene administration used in the studies, variability in duration
of treatments, mice age groups, and different AD mouse models
used in the studies. Another potential problem with interpret-
ing these results is that speciﬁc RyanR inhibitors do not exist and
the drug dantrolene used in most studies has additional targets
such as store-operated Ca2+ channels (Zhao et al., 2006). More-
over, dantrolene is speciﬁc for skeletal muscle RyanR1 (Krause
et al., 2004), and does not block neuronal RyanR2 and RyanR3
subtypes effectively. To resolve this controversy, our laboratory is
currently taking a genetic approach to evaluate a role of RyanRs
in AD. Our initial results indicate that RyanR may play initially
compensatory and later detrimental role in the context of AD
pathology.
Taking together, it is clear from multiple studies with various
AD cellular and animalmodels that ERCa2+ signaling is disturbed
in AD and that activity of both InsP3R and RyanR is enhanced.
Increased expression of RyanRs at least partially responsible for
enhanced CICR in AD neurons. The mechanisms responsible for
enhanced activity of InsP3R are less certain andmay involve direct
gating of InsP3R by presenilins. It is also likely that increased
ER Ca2+ levels contribute to enhanced RyanR-mediated and
InsP3R-mediated Ca2+ release, as discussed in more details in
the following section. It also appears that RyanR is a potential
pharmacological target for AD treatment and that dantrolene
may provide potential avenue for suppressing RyanR activity
in AD.
PRESENILINS
There aremutations inpresenilin 1 (PSEN1), presenilin 2 (PSEN2),
and APP genes that are linked to early onset FAD. The majority,
nearly 200, of these mutations are within PSEN1. To date many
known PSEN1 mutations contribute to Ca2+ disruptions in ER
Ca2+ signaling (Bezprozvanny and Mattson, 2008). PS1 and PS2
constitute the catalytic pore of the γ-secretase complex, other part-
ner of the complex are nicastrin, aph-1, and pen-2 (De Strooper,
2003). The γ-secretase complex cleaves type-1 transmembrane
proteins, including Notch receptor protein and APP. One of the
main therapeutic approaches to AD is focused on development of
γ-secretase inhibitors (GSIs) and modulators, however so far this
approach has failed in phase III clinical trials of Eli–Lilly’s Sema-
gacestat, a non-selective GSI (Doody et al., 2013). Semagacestat
treatment resulted in worsen cognition scores and increase in the
risk of skin cancer (Doody et al., 2013), most likely due to inhibi-
tion of Notch processing. As a result, clinical trials of GSIs have
been halted.
In addition to contributing to altered γ-secretase function in
AD pathogenesis, FAD PS mutations result in disturbed Ca2+
signaling in neurons (reviewed in Stutzmann, 2007; Bezproz-
vanny andMattson, 2008; Supnet and Bezprozvanny, 2010a,b). As
discussed above,multiple studies demonstrated enhanced InsP3R-
mediated and RyanR-mediated ER Ca2+ release in PS-FAD cells.
Presenilin mutations also affected SOC, a reﬁlling mechanism for
ER stores (Leissring et al., 2000; Yoo et al., 2000; Giacomello et al.,
2005; Zhang et al., 2010b). To explain these ﬁndings, it was sug-
gested that gating of InsP3R or RyanRs directly modulated by
presenilins (Cheung et al., 2008, 2010; Rybalchenko et al., 2008).
It was also suggested that presenilins potentiate activity of sarco-
/endoplasmic reticulumCa2+ ATPase (SERCA;Green et al., 2008),
a mechanism that could contribute to the overﬁlling of ER Ca2+
store.
Our laboratory offered an alternative mechanistic explanation
for most of these ﬁndings by demonstrating that wild type PSs
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function as ER Ca2+ leak channels (Tu et al., 2006), which func-
tion tomaintain ER Ca2+ homeostasis by constantly leaking Ca2+
into the cytosol and balancing SERCA activity. Our results sug-
gested that presenilin holoproteins function as low conductance
passive ER Ca2+ leak channel, and that ER Ca2+ leak function
of presenilins does not depend on their γ-secretase activity (Tu
et al., 2006). Moreover, we found that some, but not all, FAD
PS mutations disrupt Ca2+ leak function (Tu et al., 2006; Nelson
et al., 2007, 2010), leading to the overﬁlling of ER with Ca2+ and
exaggerated ER Ca2+ release observed in PS1/PS2 FAD mutants
ﬁbroblasts (Tu et al., 2006; Nelson et al., 2007, 2010), cultured hip-
pocampal neurons from 3xTg AD neurons (Zhang et al., 2010b),
andprimary lymphoblasts fromFADpatients (Nelson et al., 2010).
These data suggest that mutations in presenilins directly linked
to deranged Ca2+ signaling and neuronal dysfunction in AD by
causing ER Ca2+ overload. Our hypothesis has been directly chal-
lenged, in particular by the group of Dr Kevin Foskett (Shilling
et al., 2012). These authors claimed that presenilin does not have
a pore and cannot act as an ion channel (Cheung et al., 2008;
Shilling et al., 2012). As we previously outlined, a number of seri-
ous technical and experimental issues exists with their negative
arguments (Bezprozvanny et al., 2012). Other experiments that
oppose to our hypothesis have also been reported (Zatti et al.,
2004, 2006). In contrast to our ﬁnding, the authors of these papers
observed that FAD-PS expression lower the ER calcium content
(Zatti et al., 2004, 2006). Despite existence of these controversial
results independent experimental support for leak function of pre-
senilin recently began to accumulate (Das et al., 2012). In a recent
study, Bandara et al. (2013) performed an unbiased RNAi-based
screen for modulators of calcium homeostasis in HEK293 cells.
They transfected 250 candidate short-interfering RNAs (siRNAs)
into the cells and used the mathematical model to quantify the
effects of knockdown on calcium pump and leak rates, which
resulted in the identiﬁcation of proteins involved in the elusive
ER Ca2+ leak pathway. Knocking down presenilin-2 or ORAI2
dramatically reduced ER calcium leak rate, and knocking down
PEN-2, encoded by PSENEN, greatly increased calcium leak rate
(Bandara et al., 2013). Knockdown of PSENENwould inhibit pro-
teolytic processing of presenilins and thus increase the holoprotein
form of the protein, which is the form of presenilins that func-
tions in ER calcium leak according to our previous experiments
(Tu et al., 2006). Thus, enhanced ER calcium leak resulting from
PEN-2 knockdown most likely reﬂects the accumulation of the
presenilin holoprotein in the ER. As discussed in the recent review
article (Bezprozvanny,2013) these ﬁndings provide strong support
to our hypothesis that presenilin holoprotein functions as ER cal-
cium leak channel. Interestingly, Honarnejad et al. (2013) recently
reported that there is PS holoprotein upregulation in human AD
brain samples, suggesting a possibility of compensatory upregula-
tion of leak pathway in AD neurons in order to reduce ER Ca2+
overload.
Where is an ion conduction pore of presenilin leak channel?
From the structural-functional analyses we suggested that trans-
membrane domains 7 and 9 but not transmembrane domain 6
may play a role in forming the ion conductance pore of PS1
(Nelson et al., 2011). Recent publication reported the ﬁrst crystal
structure of archeal homolog of presenilin (PSH; Li et al., 2013).
These authors discovered that PSH has a large hole that transverse
the entire protein and is surrounded by transmembrane domains
2, 3, 5, and 7. These data are in good agreement with ourmutagen-
esis mapping studies (Nelson et al., 2011). Moreover, these authors
postulate that the hole is large enough to allow passage of the small
ions (Li et al., 2013), suggesting that PSH may function as an ion
channel. Importantly, the motifs that constitute catalytic core are
conserved between PSH and PS1, therefore the structure of PS1
should be very similar to the structure of PSH.
STORE-OPERATED CALCIUM CHANNELS
Recent growing evidence suggests that SOC channels may be
involved in AD pathogenesis. SOC channels are unique in the
nature of their activation. They are activated in response to low-
ering of Ca2+ content in ER. The ﬁrst reports about role of
SOC channels in the pathogenesis of AD have been published
in 2000. Leissring et al. (2000) observed that ﬁbroblasts isolated
from PS1-M146V knock in mice exhibit signiﬁcant impairments
in store-operated Ca2+ entry after stimulation of cells with
bradykinin. These authors suggested that impaired SOC in these
cells is due to elevated ER Ca2+ levels in PS1-M146V ﬁbrob-
lasts (Leissring et al., 2000). In the same year Yoo et al. (2000)
reported alteration in SOC activity in presenilin FAD mutant
neurons. Two different mechanisms of mutant PS1-mediated dys-
regulation of SOC have been proposed (Herms et al., 2003). The
ﬁrst mechanism is linked to direct attenuation of SOC at the cell
surface, the second mechanism evokes changes in processing of
APP and generation of amyloid peptides (Herms et al., 2003).
However, second mechanism cannot explain alterations of SOC
observed in the absence of human APP and Aβ42 accumulation.
TRP channels may play a role in disruption of neuronal SOC
in AD (Yamamoto et al., 2007), but the mechanisms involved in
changes in TRP channel expression or activity in AD are poorly
understood.
In addition to TRP channels, important players of SOC in
excitable and non-excitable cells are stromal interaction molecule
1 and 2 (STIM2) proteins. STIM1 and STIM2protein reside in ER,
and reduction in ER Ca2+ levels causes oligomerization of STIMs,
translocation to plasma membrane, and activation of SOC chan-
nels (Liou et al., 2005). The molecular identity of neuronal SOC
is poorly understood, but most likely involves complex of STIMs
with TRP channels and/or Orai proteins (Figure 1). Interestingly,
changes in expression of STIM1 and STIM2 proteins were found
in PS knockout and FAD mutant cells (Bojarski et al., 2009), sug-
gesting a possible mechanism for SOC dysregulation. In recent
review articles we suggested a possible connection between dysreg-
ulated neuronal SOC and synaptic spine maintenance in AD and
aging brains (Popugaeva et al., 2012; Bezprozvanny andHiesinger,
2013). These ideas are currently being tested experimentally in
our laboratory. Another possibility involves potential connection
between impaired neuronal SOC and abnormal synaptic vesicle
recycling in PS mutant neurons (Zhang et al., 2009, 2010a).
SUMMARY
In the summary we would like to conclude with our working
hypothesis for ER Ca2+ dysregulation in AD (Figure 1). FAD
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linked mutations in PS cause disruption of PS Ca2+ leak func-
tion. As a result Ca2+ is accumulating inside of the ER. Similar
increase in ER Ca2+ levels occur as a result of brain aging. In
order to compensate for ER Ca2+ overload neurons mount two
physiological responses: (1) upregulate gating of InsP3R and
expression/activity of RyanR, and (2) downregulate activity of
neuronal SOC (Figure 1). We hypothesize that these initially
protective responses with time become toxic and eventually lead
to synaptic dysfunction, synaptic loss, impaired plasticity, and
learning, loss of memories and neurodegeneration. The role of
RyanR in these processes is likely to be more signiﬁcant than
the role of InsP3R, as InsP3R predominantly localized in the
soma, whereas RyanR are abundant in the postsynaptic and
presynaptic terminals. Dantrolene provides a possible way to
suppress RyanR-mediated Ca2+ release pharmacologically, but
there are signiﬁcant issues with speciﬁcity of dantrolene effects
and its delivery to the brain. Neuronal SOC pathway provides a
novel potential target for AD treatment that should be explored
further.
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